TAFI polyclonal Antibody | BS62323

TAFI polyclonal Antibody | BS62323 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200

Background: The Thrombin-activatable fibrinolysis inhibitor (TAFI), also designated procarboxypeptidase B2 or procarboxypeptidase U, is a hepatically secreted zymogen that downregulates fibrinolysis when activated by Thrombin. It is synthesized in the liver and circulates in plasma in its proenzyme form. When activated, TAFI removes C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins. TAFI cleaves the lysine residues from Fibrin, which prevents plasminogen from activation into plasmin and retards the lysis of a Fibrin clot. Elevated concentration of TAFI in blood is considered a risk factor for venous thrombosis, whereas a deficiency might contribute to the severity of bleeding disorders in hemophilias A and B. Decreased levels of TAFI are found in chronic liver disease.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: TAFI polyclonal Antibody detects endogenous levels of TAFI protein.

Molecular Weight: ~ 48 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Carboxypeptidase B2; Carboxypeptidase U; CPU; Plasma carboxypeptidase B; pCPB; Thrombin-activable fibrinolysis inhibitor; TAFI; CPB2

Immunogen: Synthetic peptide, corresponding to Human TAFI.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: